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Abstract 
A new technology has been developed to overcome the delivery problem of peptide drugs. 
The technique utilizes a hydrocarbon linker (“staple”) to stabilize a peptide in a helical 
configuration to promote cellular uptake.   Here we investigate whether stapled peptides are 
intrinsically membrane permeable, by performing a case study on a stapled 12-mer peptide (an 
HIV-1 inhibitor CAI) named NYAD-1.  We found that NYAD-1 indeed permeates through a 
lipid bilayer even at low solution concentrations.  In order to understand the reason for the 
membrane permeability, we investigated the physical properties of peptide-lipid mixtures as a 
function of bound peptide-to-lipid molar ratio P/L.  We found that NYAD-1 spontaneously binds 
to a lipid bilayer and subsequently exhibits three different states as P/L increases.  At low P/L, 
the peptide primarily binds on the polar-apolar interface of the bilayer that has the effect of 
stretching the membrane area and thinning the membrane.  The thinning effect reaches its 
maximum at P/L ~1/12.  Further binding goes into the hydrocarbon region that has little thinning 
effect but continues to increase the membrane area.  When the membrane area expanded 10-13%, 
transmembrane pores begin to appear in the bilayer.  We believe that these membrane bound 
states explain the membrane permeability of NYAD-1at low peptide concentrations. 
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INTRODUCTION 
The lipid matrix of a cell membrane provides a hydrophobic barrier that defines the 
boundary of the cell.  An intact membrane is crucial for cell function but it is also a major 
impediment for the delivery of therapeutic agents into cells.  This is so even if the drug enters the 
cell by endocytosis—in such a case, drug still needs to cross the endosomal membrane.  In recent 
years a new type of drug technology called stapled peptides has been developed and adopted by 
the pharmaceutical industry.  An all-hydrocarbon “staple” cross-links a peptide at i and i+4 or 
i+7 position to increase it’s α-helix propensity (1-7).  The rationale for the stapled peptides is 
three-fold (1): 1) stabilizing the peptide in a  configuration that matches the binding site of the 
protein target, 2) protecting the peptide against proteolytic action and 3) making the peptide 
membrane permeable.  While the functionality and stability of stapled peptides are 
understandable, it is not clear why the stapled helicity would facilitate cell uptake.  Notably these 
stapled peptides bypass the Lipinski rules which stipulate that the molecular mass of a drug 
should not exceed 500 daltons (6, 8).  Stapled peptides are several times that size, and yet still 
traffic to the intracellular targets (2, 4, 7).  The goal of our study is to investigate first, if the 
peptides indeed gain membrane permeability by the stapling modification, and second, if so what 
could be the underlying mechanism for the membrane transmission property.   We hope to 
provide a rational basis for the use of this new drug delivery technology.  Understanding the 
mechanism for membrane transmission will facilitate the development of strategies for drug 
delivery. 
We studied a stapled peptide called NYAD-1 based on a 12-mer peptide (CAI) that has 
been found to target the capsid of human immunodeficiency virus type 1 (HIV-1).   CAI inhibits 
HIV-1 assembly in vitro; however it failed to inhibit HIV-1 in cell culture.  The X-ray crystal 
structure of CAI in complex with the C-terminal domain of capsid (C-CA) revealed that the 
peptide adopts an α-helical conformation (4, 9).  Accordingly Zhang et al. (4) used the 
hydrocarbon stapling technique (1-3) to convert CAI into a stable helical peptide named NYAD-
1.  Subsequently the authors showed the anti-HIV-1 activity of NYAD-1 in cell culture and that 
the stapled peptide indeed targeted the C-CA.  However, cellular uptake is not a proof of self-
permeating through the membrane.  For example, cellular uptake of various cell penetrating 
peptides has been widely reported, yet the mechanisms of cell penetrating peptides are still being 
debated (10, 11). 
With a fluorescence-labeled NYAD-1 (named NYAD-2) we found that the peptide 
indeed permeates across lipid bilayers.  In order to understand what properties of the peptide 
enable the membrane permeability, we further studied the properties of NYAD-1mixed in lipid 
bilayers as a function of peptide-to-lipid ratio.  The property of NYAD-1 in lipid bilayers is 
unlike other peptides or membrane-binding drugs we have studied before, including 
antimicrobial peptides, amyloidogenic peptides and amphipathic drugs.    We offer a simple 
explanation for why a peptide gains membrane permeability by hydrocarbon stapling. 
 
EXPERIMENT 
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Materials and sample preparation 
NYAD-1 is H - Ile - Thr - Phe - X - Asp - Leu - Leu - X - Tyr - Tyr - Gly - Pro - NH2 
[with special cyclization to get double bond, X= (S) - alpha - (2’-pentenyl)alanine] (4).  NYAD-1 
and CAI (H-Ile-Thr-Phe-Glu-Asp-Leu-Leu-Asp-Tyr-Tyr-Gly-Pro-NH2) were synthesized by 
CPC Scientific Inc (San Jose, CA) under the supervision of Xiaohe Tong, one of the authors of 
(4).  NYAD-2 is FITC - (beta - Ala) - Ile - Thr - Phe - X - Asp - Leu - Leu - X - Tyr - Tyr - Gly - 
Pro - NH2 (with special cyclization to get double bond, X= (S) - alpha - (2’- pentenyl)alanine; 
FITC = fluorescein isothiocyanate) synthesized by AnaSpec (Fremont, CA).   1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (Rh-DOPE) were purchased from Avanti Polar Lipids 
(Alabaster, AL). Texas red dextran (TRD) (MW 625 and 10000) and calcein (MW 623) were 
purchased from Invitrogen Probe (Grand Island, NY).  Fluorescein PEG (MW 1000), was 
purchased from NANOCS (Boston, MA).  All other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO) and were used without further purification.  All experiments were 
performed at room temperature ~25o C. 
 
Giant unilamellar vesicles (GUVs) were produced by the electroformation method (12) in a 
production chamber containing a GUV interior solution.  The solution includes ~200 mM sugar 
(sucrose or glucose) to control the osmolality and also a pH buffer and solution dyes if necessary.  
The osmolalities of the solutions used for GUV interior and GUV exterior were measured 
separately by a Wescor Model 5520 dew-point Osmometer (Wescor, Logan, UT).  Equi-
osmolality between the inside and outside of the GUV was the initial condition in all GUV 
experiments.  To produce GUVs, DOPC or DOPC and 0.5% molar ratio of Rh-DOPE were 
dissolved in 1:1 (v/v) tetrafluoroethylene and chloroform.  The lipid solution (~0.05 mg lipid) 
was deposited onto two ITO coated glass cover slips.  After drying under vacuum, an o-ring was 
sandwiched between two ITO slips and the gap was filled with the interior solution.   3 V ac at 
10 Hz was applied between the two ITO electrodes for 2 h.  Subsequently the frequency was 
adjusted to 5 Hz for 10 mins and followed by 1 Hz for 10 mins.  This electroformation method 
has been shown to produce unilamellar large vesicles (12).  The GUV suspension was then 
gently collected in a glass vial (reservoir).  The vesicles were used within 24 hrs of production. 
 
Aligned multilamellae of peptide/lipid mixtures were prepared by first dissolving the peptide 
and lipid of chosen molar ratio, P/L, in 1:1 (v/v) tetrafluoroethylene and chloroform.  The 
mixture was uniformly spread on a thoroughly cleaned fused-quartz substrate (0.018 mg peptide 
on a 1 cm2 quartz plate for P/L>1/30; 0.3 mg of lipid on a 1 cm2 plate for P/L≤1/30).  After the 
solvent evaporated in vacuum, the sample was hydrated with saturated water vapor in 37o C oven 
overnight.  The results were well-aligned parallel bilayers, as proven by x-ray diffraction.  
During the experiment, the samples were housed in a temperature humidity chamber in which 
the hydration level of the sample was controlled by the relative humidity (RH) of water vapor 
(13).  
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Aspirated GUV experiment 
The experimental setup for aspirated GUV experiment was described in Sun et al (14).  
Before the experiment, micropipettes (with inner diameter 16-20 μm) and the walls of sample 
chambers were coated with 0.5% bovine serum albumin in order to dissipate the charge on the 
glass surface and then washed extensively with water.   The micropipette was connected to an 
oil-filled U tube where a negative pressure was produced and controlled by reference to the 
atmosphere pressure (15). 
A selected GUV (diameter ~40-70 µm) in the reservoir was aspirated at a low constant 
negative pressure (~100 Pa producing a membrane tension ~0.4 mN/m) by a micropipette, and 
transferred via a transfer pipe (14) to an observation chamber where the solution contained the 
peptide.  Note that CAI, NYAD-1or NYAD-2 was added to the solution by first dissolving in 
DMSO.  It is known that DMSO partially permeates through lipid bilayers (16).  In order to 
avoid the effect of DMSO on osmolality balance (16), the same concentration of DMSO was also 
added to the interior solution, so that the osmolality of the solution in the observation chamber 
was the same as that of the GUV interior solution.  The response of the GUV to the peptide 
binding was observed by a conventional inverted widefield microscope (IX81, Olympus, Tokyo, 
Japan) and recorded by a Hamamatsu Photonics digital CCD Camera (model C10600-10B) 
(Hamamatsu City, Japan), or a confocal microscopy (Nikon C1 si-LU4A confocal spectral 
imaging system and Nikon C2 confocal laser point scanning system—Tokyo, Japan) with 
488nm/561nm lasers (OBIS/Sapphire, Coherent, Santa Clara, CA). 
In response to peptide binding, a GUV can potentially change its membrane area A and 
volume V.  The protrusion inside the micropipette serves as an amplifier for the measurement of 
such changes.  From the microscopic images, pL the length of the protrusion, pR  the radius of 
the micropipette, and vR the radius of the GUV were carefully measured.  Then it is 
straightforward to show  ∆𝐴 = 2𝜋𝑅𝑝∆𝐿𝑝 + 8𝜋𝑅𝑣∆𝑅𝑣, and ∆𝑉 = 𝜋𝑅𝑝2∆𝐿𝑝 + 4𝜋𝑅𝑣2∆𝑅𝑣 (17).  In 
general the changes of GUV radius ∆Rv were too small to be measured accurately.  However as 
long as the inside and outside of the GUVs were isotonic, there should be no change of volume.  
Under the condition ∆V = 0, ∆Lp is directly proportional to ∆A: ∆𝐴 = 2𝜋𝑅𝑝�1 − 𝑅𝑝 𝑅𝑣⁄ �∆𝐿𝑝.  
This is the case when the peptide binds to the GUV but does not cause any molecular leakage; 
the protrusion length increase ∆𝐿𝑝 > 0 indicates an area expansion ∆𝐴 > 0. 
On the other hand, if peptides induce formation of finite-sized transmembrane pores, the 
influx of glucose will be greater than the efflux of sucrose through the pores, because sucrose is 
approximately two times as large as glucose.   The resultant osmolality imbalance induces a net 
water influx, causing a volume increase in the GUV.  If the membrane area is constant, the 
relation between ∆Lp and ∆V is ∆𝑉 = −𝜋𝑅𝑝�𝑅𝑣 − 𝑅𝑝�∆𝐿𝑝.  Thus the GUV protrusion length 
would decrease, ∆𝐿𝑝 < 0, when peptides induce pores in the membrane (18, 19). 
To make a plot for aspirated GUV experiments, the protrusion length increase is 
converted to increasing ∆𝐴/𝐴, using the relation ∆𝐴 = 2𝜋𝑅𝑝�1 − 𝑅𝑝 𝑅𝑣⁄ �∆𝐿𝑝, so that different 
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size GUVs can be compared with each other.  However when pores are formed, the decrease of 
𝐿𝑝 is not a decrease of A as explained above.  Nevertheless, we still use the relation ∆𝐴 =2𝜋𝑅𝑝�1 − 𝑅𝑝 𝑅𝑣⁄ �∆𝐿𝑝 to show the decrease of 𝐿𝑝 in the ∆𝐴/𝐴 plot.  Thus a decreasing ∆𝐴/𝐴 is 
used to indicate pore formation in the ∆𝐴/𝐴 plot, not a decrease in membrane area. 
   
GUV Leakage experiment 
 For leakage experiment, the GUV interior solution also contained 30 µM calcein and 50 
µM TRD10000. Two observation chambers containing the same solution 190 mM glucose and 
10 mM HEPES pH 7 were set side by side.  About 10 μL of the GUV suspension was injected 
into the first observation chamber and well-mixed with the solution in the chamber by stirring. 
About ten GUVs were transferred from the first to the second chamber via a transfer pipe. The 
purpose of this two-chamber procedure was to dilute the untrapped calcein and TRD in the 
solution external to the GUVs. In the second chamber, the GUVs settled at the bottom due to the 
density differential and were observed by a widefield microscope.  The effect of peptide-induced 
leakage was observed by slowly injecting a small amount of isotonic solution containing NYAD-
1 until the peptide concentration equal to 25 µM. 
 
Membrane permeation experiment 
We used FITC labeled NYAD (called NYAD-2) to observe membrane permeation. The 
fluorescence intensity of NYAD-2 depends on the pH value.  This was a problem, because in 
general the GUV production by the electroformation method (12) is difficult in ionic solutions, 
for example in pH 7.  Fortunately the production of GUVs in pH 9 was possible.  Thus we 
investigated the permeation of NYAD-2 with a pH 7 solution outside and a pH 9 solution inside 
the GUV.  
The interior solution for GUV production was 210 mM sucrose, 10 mM Tris buffer pH 9, 
10µM TRD625 and 2.82mM DMSO.  One control chamber and one observation chamber were 
used for the permeation experiment. Both chambers contained 210 mM glucose, 10 mM Tris 
buffer pH 7 and 2.82mM DMSO; only the observation chamber contained 2 µM NYAD-2. A 
GUV aspirated from the production chamber was first transferred to the control chamber to 
dilute the TRD in the exterior solution, and then transferred to the observation chamber for 
observation by the confocal microscope.  The image was recorded in two channels 488 nm for 
FITC and 561 nm for TRD.  The recording time was 0.5 s at 1 min interval to avoid excessive 
photobleaching.   
 
X-ray diffraction experiment 
Multilamellar samples were measured in a temperature-humidity chamber (13).  ω-2θ 
diffraction was collected on a four-circle Huber goniometer (Huber Diffraktionstechnik, 
Rimsting, Germany), with a vertical line-focused Cu Kα source (λ=1.542 Å) operating at 35 kV 
and 15–30 mA. The incident beam was collimated by a horizontal soller slit and two vertical slits 
on the front and the back sides of the soller slit. The horizontal and vertical divergences of the 
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incident beam were 0.23⁰ and 0.3⁰, respectively. The diffracted beam ﬁrst passed through a 
vertical slit and then was discriminated by a bent graphite monochromator (selected for 1.542 Å) 
before entering a scintillation detector.  Thus the detector excluded Compton scattering, 
ﬂuorescence and most of the X-rays from air scattering. This diffractometer was designed to 
minimize the background signal, thus allowing the measurement of high diffraction orders. 
Before the measurement, the aligned multilayer sample was carefully positioned at the 
center of the X-ray beam and was oriented so that ω = 0⁰ and θ = 0⁰ coincided.  We have 
established an elaborate routine for positioning and orienting the sample as described in Wu et al. 
(20).  A two-dimensional ω-θ scan around the second or the third Bragg order was used to check 
the alignment of the ω-angle and the mosaic of the multilayers alignment.  Typically the FWHM 
(full width half maximum) of the peak on the ω axis (of the ω- θ scan) was 0.2-0.3⁰ (example in 
(21)).  Once the sample was properly positioned and aligned on the diffractometer, each ω-2θ 
scan was performed from ω=0.5⁰ to ω=7.5⁰ with a step size of ∆ω=0.01⁰. An attenuator was 
used to prevent the ﬁrst-order Bragg peak from saturating the detector.  The scan was repeated 
2–3 times at each of several hydration levels and averaged at each hydration level for data 
analysis.   Measurements at several hydration levels were for the purpose of phase determination 
by the swelling method.  Only the results of 98% RH are reported. (At RH above 98%, 
membrane samples tended to flow.) 
The procedure of data reduction was described in many of our previous works (22, 23). 
Brieﬂy, the measured diffraction intensity was ﬁrst corrected for the attenuator absorption and 
for the detector’s dead-time factor. After removing the background, data were corrected for 
sample absorption and diffraction volume. The integrated peak intensities were then corrected 
for the polarization and the Lorentz factors. The relative magnitude of the diffraction amplitude 
was the square-root of the integrated intensity.  With their phases determined by the swelling 
method, the diffraction amplitudes were used to reconstruct the electron density proﬁle of the 
bilayer.  Across the bilayer profile, the phosphate peak to phosphate peak distance (PtP) was 
measured for the bilayer thickness.  Measurements by the above described procedure have been 
done for various peptide-lipid mixtures for more than a decade, e.g., (20, 21, 23).  We found in 
each case the measured PtP reproducible within ±0.2 Å. 
 
RESULTS 
(1) Aspirated GUV experiment 
 Fig. 1 shows separately the responses of a DOPC GUV to CAI, NYAD-1 and NYAD-2 
all at the same concentration 8 µM at pH 7.  There was no indication of CAI binding to the GUV 
over a long time (Fig. 1A).  The very slow increase of the protrusion length was the same as in a 
control run with no peptide.  The background increase (in the absence of peptides) was caused by 
a slow increase of osmolality in the exterior solution due to water evaporation. A higher 
osmolality in the exterior solution caused an efflux of water from the GUV.  A decrease of GUV 
volume at constant membrane area caused an increase of the protrusion length.  The experiment 
with CAI was repeated many times at different peptide concentrations (highest 40 µM) with the 
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same result, all similar to the background increase.  The conclusion is that CAI does not bind to 
the lipid bilayers. 
In the presence of 8 µM NYAD-1, the protrusion length immediately increased and 
reached a maximum within 15 s (Fig. 1B and 1D).  This implies that during this time the peptide 
binding increased the bound ratio P/L, without causing molecular leakage.  After reaching a 
maximum length, the protrusion length decreased indicating pores were formed in the membrane 
as explained in the experimental section.  In this case, the background protrusion length increase 
was negligible in such a short time duration.  From the maximum protrusion length increase, we 
calculate the maximum fractional area increase to be ∆𝐴/𝐴 = 11 − 13% (Fig. 1D).  At lower 
NYAD-1 concentrations, e.g., 4 µM, the ∆𝐴/𝐴  curves looked the same, also increased to 
∆𝐴/𝐴 = 10 − 15% except that the time for reaching the maximum stretched to 60-100 s. 
The same experiment was repeated for NYAD-2 to show that the FITC label on NYAD-1 
did not alter the peptide’s characteristic property (Fig. 1C and 1E).  The modification by the 
FITC label considerably slowed the action of the peptide, indicating a lower binding coefficient 
to the bilayer (note the time scale).  Nevertheless NYAD-2 also increased the protrusion length 
to a maximum and then caused its decrease, showing its pore forming capability.  Because the 
experiment lasted for a long time compared with NYAD-1, a significant portion of the protrusion 
length increase was due to the osmolality increase in the exterior solution, caused by water 
evaporation as explained above. 
 
(2) Leakage experiment 
Fig. 2 demonstrates molecular leakage induced by NYAD-1 at high concentrations.  A 
GUV containing green dye calcein (MW 623) and red dye TXD10000 (MW 10000) was in the 
observation chamber containing a solution of 190 mM glucose and 10 mM HEPES (pH 7).  
NYAD-1 in the same solution was slowly injected into the observation chamber until its final 
concentration was 25 µM. After a while (this time depended on the distance and speed of 
injection) both dyes were observed to leak out, while the GUV membrane remained intact.  
Understandably the leakage of calcein was faster than TRD10000 due to the difference in 
molecular weight. When the same leakage experiment was performed with antimicrobial peptide 
magainin, the pores at first allowed both large and small dye molecules to leak out but after a 
while only small molecules continued to leak out, implying pore size reduction with time (24).  It 
is not clear from our leakage curves whether the large dye would leak out completely.  It is clear 
that at high concentration, NYAD-1 induces pores in membranes.  The pore size kinetics was not 
pursued, because it is probably of no interest to the therapeutic use of the drug at much lower 
concentrations. 
 
(3) Membrane permeability experiment 
First, we measured the fluorescence intensity of NYAD-2 at pH 9 and at pH 7, and found 
that the intensity at pH 9 was 1.7 times higher than at pH7.  Second, we used an aspirated GUV 
in a solution containing 15 µM NYAD-2 to measure the relative binding coefficients at pH 7 and 
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pH 9 (Fig. 3C).  Membrane binding was measured by the fractional area expansion ∆𝐴/𝐴 of the 
GUV.  The plateaued values of ∆𝐴/𝐴 indicated that the binding coefficient of NYAD-2 to 
DOPC GUV at pH 7 is 2 to 3 times higher than at pH 9.  
Because NYAD peptide forms pores at high concentrations, the permeation experiment 
was conducted at a low peptide concentration (2 µM) to avoid pore formation.  Note that at 15 
µM NYAD-2, the time for ∆𝐴/𝐴 to plateau was ~ 2 min. We expected the permeation 
experiment to last much longer. To avoid photobleaching, we set the measurement interval 1 min 
for fluorescence intensity measurement. An aspirated GUV was imaged in the control chamber 
(where there was no NYAD-2) right before it was transferred to the observation chamber.  It 
took ~ 1.5 min to readjust the confocal focus after the aspirated GUV was transferred to the 
observation chamber.  Therefore the first point of observation was ~1.5 min after the GUV was 
exposed to 2 µM NYAD-2.  The result is shown in Fig. 3.  The protrusion length increased 
without any sign of decrease, indicating peptide binding without molecular leakage.  The 
absence of molecular leakage was reconfirmed by the constant intensity of TRD625 inside the 
GUV.  The fluorescent intensity of each dye was corrected by a background reading without the 
dye.  The steady increase of the FITC fluorescence intensity inside the GUV indicates 
permeation of NYAD-2 through the GUV membrane. 
For a null control experiment, the same permeability experiment was performed with 
fluorescein PEG (1000) replacing NYAD-2.  As expected, no fluorescein PEG was detected 
inside the GUV. 
 
 (4) Membrane thinning by NYAD-1 binding 
Electron density profiles obtained by X-ray diffraction show that the peptide-lipid 
mixtures formed well defined lipid bilayers (Fig. 4 A,B).  The electron density of the peptides 
did not show up in the diffraction-based profiles, because the peptide positions were not 
correlated from bilayer to bilayer (diffraction is the result of electron density correlations (25)).  
However, whether the peptides were located on the polar-apolar interface or inserted in the 
hydrocarbon chain region, either condition was expected to increase the chain disorder.   Indeed 
the central region of the profile was increasingly smoothed out as P/L increases (Fig. 4B).  The 
most important effect of peptide binding is measured by the phosphate peak to phosphate peak 
distance across the bilayer (PtP).  PtP is a measure of the bilayer thickness.  It decreases more or 
less linearly with P/L up to ~ 1/12 and levels off for P/L >1/12 (Fig. 4C).  This transition point 
(~1/12) is called the threshold value P/L*.  Previous studies on antimicrobial peptides (AMPs) 
(26, 27) showed that AMPs caused a linear decrease of PtP with P/L and followed by a PtP 
leveling off, similar to NYAD-1.  Neutron in-plane scattering showed that transmembrane pores 
were formed in the bilayers for P/L >P/L* but no pores were detected for P/L < P/L* (28-30).  
Thus for AMPs, P/L* is the threshold concentration for pore formation. 
Membrane thinning and membrane area expansion are related due to the near 
incompressibility of the hydrocarbon volume in the chain region of lipid bilayer (31).  The 
hydrocarbon volume is the membrane area A times the thickness of the hydrocarbon region h 
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which can be obtained from PtP by ℎ ≈ 𝑃𝑡𝑃 − 10 Å, namely, PtP minus twice the length of the 
glycerol region (from the phosphate to the first methylene of the hydrocarbon chains) (32, 33).  
The incompressibility of lipid chain volume, ∆(𝐴 ∙ ℎ) = 0, leads to an equality between the 
fractional area expansion and the fractional membrane thinning: ∆𝐴/𝐴 = −∆ℎ/ℎ.  For NYAD-1 
at P/L* ~ 1/12, when the membrane thinning reaches the maximun (Fig. 4D), the fractional 
thinning is (−∆ℎ/ℎ)𝑚𝑎𝑥~8%.  At the corresponding value of membrane expansion ∆𝐴/𝐴~8% 
in the GUV experiment, no pores were formed (Fig. 1D).  Thus NYAD-1 is distinctly different 
from AMPs, although it is capable of pore formation. 
 
DISCUSSION 
A method for measuring membrane permeation 
It is commonly assumed that a membrane-binding amphipathic molecule would bind on 
the outer leaflet of the membrane bilayer and would not translocate across the membrane.  This 
is undoubtedly the case if the molecule is a globular protein and only a portion of the protein 
binds to the outer leaflet. For small drugs, the Lipinski rules disfavor the membrane permeation 
of molecules larger than 500 daltons (6, 8). Thus the questions are for membrane active peptides 
of molecular weights from 1000 to 4000 daltons, such as AMPs, cell penetrating peptides and 
peptide drugs.  Does each of them permeate across the membrane upon binding?  The answers 
are directly related to their functions in the case of cell-penetrating peptides and drugs or to their 
mechanisms in the case of AMPs.  For example, it has been argued that pore formation by AMPs 
is due to the stress of asymmetric binding to the outer leaflet (24). To our knowledge, few 
permeability experiments have been performed so far, probably because of the difficulty of 
detecting the peptides and also because a meaningful test must be conducted at biologically 
relevant concentrations which are usually low.  In the case of pore forming peptides, the test 
must be performed without pore formation. 
For the drug NYAD, we have shown that the FITC labeled NYAD-2 has the same 
characteristic property of NYAD-1 in membrane interactions.  Two factors favor the permeation 
experiment with NYAD-2. First, we discovered that it was possible to produce GUVs in a pH 9 
solution (although not in pH 7).  A previous experiment by Zhou and Raphael (34) showed that 
there was little change of bilayer elastic properties between pH 7 and pH 9.  The fluorescence 
intensity of NYAD-2 at pH 9 was measured to be 1.7 time higher than at pH 7.  Thus if NYAD-2 
does permeate into the interior of GUV, the fluorescence intensity would be enhanced for 
detection. Second, we found that the binding coefficient of NYAD-2 to DOPC GUV at pH 7 is 2 
to 3 times higher than at pH 9 (Fig. 3C).  That means that at a given surface bound concentration 
of NYAD-2 on the membrane, the equilibrium solution concentration of NYAD-2 at pH 9 is 2 to 
3 times larger than the equilibrium solution concentration at pH 7. Thus, supposing that NYAD-2 
is freely permeating across the membrane, the equilibrium NYAD-2 concentration at pH 9 inside 
the GUV would be 2 to 3 times higher than the equilibrium NYAD-2 concentration at pH 7 
outside the GUV.   
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The permeation experiment (Fig. 3A, B) clearly shows that NYAD-2 peptides diffused 
from the outside solution into the GUV by permeating through the membrane, while the integrity 
of the membrane was assured by no decrease of the GUV protrusion length (see the experimental 
section on aspirated GUV) and no leakage of TRD625.  As predicted, the accumulated NYAD-2 
inside the GUV exceeded the outside concentration.   
 
Membrane-bound states and membrane permeability 
Although NYAD-1 induces pore formation at a very high peptide-to-lipid ratio in bilayers, 
its behavior is different from pore-forming peptides like melittin and other AMPs.  NYAD-1 and 
AMPs all initially bind to the polar-apolar interface of bilayers, where they cause membrane area 
expansion in a GUV and membrane thinning in a lipid bilayer, in direct proportion to P/L.  The 
maximum fractional membrane thinning (−∆ℎ/ℎ) 𝑚𝑎𝑥 caused by AMPs is typically in the range 
of 3 to 5 %, right before the AMPs form pores (26).  At the corresponding value of ∆𝐴/𝐴, the 
GUV begins to leak or shows signs of pore formation (19).  Thus the value of P/L when the 
maximum membrane thinning occurs is called the threshold concentration P/L* of AMPs for 
pore formation.  For AMPs, (−∆ℎ/ℎ) 𝑚𝑎𝑥 = (−∆𝐴/𝐴) 𝑚𝑎𝑥. 
NYAD-1 is fundamentally different from AMPs.  Firstly the maximum membrane 
thinning by NYAD-1 (~8%) exceeds the maximum thinning (~5%) by any AMP (26).  An ~8% 
membrane thinning is probably the physical limit of lipid bilayers, because ∆𝐴/𝐴~8% is also the 
limit of lipid bilayer area expansion by external tension (35).  Secondly when NYAD-1 binding 
caused the GUV area expansion to ∆𝐴/𝐴~8% there was no pore formation (Fig. 1D).  As the 
binding of NYAD-1 continued, the GUV continued its membrane area expansion until ∆𝐴/𝐴 =11 − 13% when pores appeared in the membrane.  The simplest explanation is that NYAD-1 
initially binds on the bilayer interface that causes both membrane area expansion and membrane 
thinning, ∆𝐴/𝐴 = −∆ℎ/ℎ in direct proportion to P/L.  But after the membrane thinning reaches 
the physical limit of  (−∆ℎ/ℎ) 𝑚𝑎𝑥 ~8%, further binding of NYAD-1 goes into the hydrocarbon 
region of the bilayer which further expands the membrane area by incorporating the peptides in 
the chain region without the effect of membrane thinning, ∆𝐴/𝐴 = (−∆ℎ/ℎ) 𝑚𝑎𝑥 + (𝑎_𝑝)/𝐴, 
where (𝑎_𝑝) is the area expansion due to NYAD-1 in the hydrocarbon region.  Only when the 
area expansion reaches ∆𝐴/𝐴~11 − 13% the pores begin to appear in the membrane—at that 
point there is a significant concentration of peptides inserted in the lipid chain region. 
The pore formation by NYAD-1 occurs at such high peptide to lipid ratios, it is probably 
irrelevant to the therapeutic use of NYAD-1. However it is the existence of bound states in the 
hydrocarbon region that makes NYAD-1 capable of translocating across the membrane.  For the 
same reason AMPs are capable of translocating across membrane by forming transient pores that 
do not allow molecular leakage but allow passage of atomic ions. It is well known that transient 
single-channels by AMPs were detected in ion conduction experiments at peptide concentrations 
in the nanomolar range (36), much lower than the pore-forming threshold concentrations of 
AMPs which are in the micromolar range (36, 37). 
12 
 
  Thus we understand the effect of a hydrocarbon-staple as follows.  First, the 
hydrocarbon link provides an amphiphathic molecular surface to an otherwise hydrophilic 
peptide.   CAI does not bind to lipid bilayers, but NYAD-1 does.  Second, the cross-linking 
stabilizes the peptide in a helical form, that is also compatible with the chain region of lipid 
bilayers.   This is not a trivial property because there are amphipathic molecules that 
spontaneously bind to the bilayer interface but do not insert into the chain region of lipid bilayers.  
Examples include tea catechin (14), penetratin (38) and islet amyloid polypeptide (IAP) (39).  
Both penetratin and IAP are random coils in solution and spontaneously bind to the bilayer 
interface as α-helices, but unlike NYAD-1, they do not insert into the hydrocarbon region.  
Experiments of penetratin and IAP showed that as each peptide concentration in the bilayer 
increased to a P/L*, both peptides turned into β-sheet-aggregates and exited from the bilayer (38, 
39).  Thus another possible function of the hydrocarbon stapling might be preventing the peptide 
from turning into β-sheet-aggregates. 
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FIGRUE LEGENDS 
Figure 1  An aspirated GUV of DOPC (and 0.5% molar ratio of Rh-DOPE) was exposed to a 
solution containing 8 µM CAI (A), 8 µM NYAD-1 (B) and 8 µM NYAD-2 (C) at pH 7.  The 
osmolalities of the interior and exterior solutions were initially balanced.  Slow water 
evaporation caused a slow increase of osmolality in the exterior solution resulting in a slow 
background increase of the protrusion length with time similar to (A), which was negligible 
within 5 mins.  (A) CAI did not cause protrusion length increase beyond the background increase, 
indicating no binding to the bilayer.  (B) and (C) NYAD-1 and NYAD-2 bound to the lipid 
bilayer and caused the protrusion length increase initially.  After the protrusion length reached a 
maximum it gradually decreased indicating pore formation.  Note the time scale differences in (B) 
and (C).  The protrusion length change in (B) and (C) was converted to the fractional area change 
∆𝐴/𝐴 in (D) and (E), respectively.  Scale bar = 25 µm. 
 
Figure 2  A GUV (DOPC) containing green dye calcein (MW 623) and red dye TXD (MW 
10000) was in an isotonic solution at pH 7.  NYAD-1 was added slowly to the outside solution 
until it reached 25 µM.  Both dyes started to leak out at the same time (time zero is an arbitrary 
reference point).  Scale bar = 50 µm. 
 
Figure 3 (A) Confocal images of an aspirated GUV (DOPC) containing 10µM TRD625 (red) 
exposed to 2 µM NYAD-2 (green).  The first image was taken in the control chamber (without 
NYAD-2) right before the transfer to the observation chamber, time = 0.  The fluorescent 
intensity of NYAD-2 inside the GUV was enhanced by the pH 9 effect (see text).  The binding of 
NYAD-2 caused the membrane expansion with no molecular leakage (protrusion length 
increase).  (The horizontal red bar on the micropipette was an optical artifact.)  Scale bar = 50 
µm. (B) Relative intensities of fluorescence: Red for TRD625 inside the GUV; Black for the 
background intensity of NYAD-2 outside the GUV; Green for the intensity of NYAD-2 inside 
the GUV normalized to the intensity outside (including the pH 9 effect).  Note that the relative 
intensity inside exceeded the intensity outside after 10 mins (see the explanation in text).  (C) 
The binding of 15 µM NYAD-2 to DOPC GUV at pH 7 and at pH 9, expressed in the fractional 
membrane area expansion ∆𝐴/𝐴.  The binding coefficient of NYAD-2 to DOPC at pH 7 is 2 to 3 
times higher than at pH 9. 
 
Figure 4  X-ray lamellar diffraction of NYAD-1 and DOPC mixtures at a series of P/L.  (A) Raw 
data of the diffraction patterns.  (B) Electron density profiles of the bilayers: Z is the distance 
from the bilayer center.  (C) The phosphate peak to phosphate peak distance across the bilayer, 
PtP, measured for a series of P/L. 
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